生活质量可预测舒尼替尼与干扰素 α 治疗转移性肾细胞癌患者的无进展生存期。
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.
机构信息
Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, IL; Pfizer Global Research and Development, Groton, CT, La Jolla, CA, and New York; Memorial Sloan-Kettering Cancer Center, New York, NY; and Massachusetts General Hospital Cancer Center, Boston, MA.
出版信息
J Oncol Pract. 2009 Mar;5(2):66-70. doi: 10.1200/JOP.0922004.
Abstract
In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for progression-free survival.
摘要
在一项随机 III 期临床试验中，与干扰素 alfa 相比，舒尼替尼作为转移性肾细胞癌的一线治疗药物，显著提高了无进展生存期。本文研究了基线生活质量以及人口统计学和临床变量是否对无进展生存期具有预测价值。
相似文献
1
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.生活质量可预测舒尼替尼与干扰素 α 治疗转移性肾细胞癌患者的无进展生存期。
J Oncol Pract. 2009 Mar;5(2):66-70. doi: 10.1200/JOP.0922004.
2
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.
3
Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore.新加坡舒尼替尼与干扰素-α一线治疗晚期和/或转移性肾细胞癌的成本-效果分析。
Int J Technol Assess Health Care. 2019 Jan;35(2):126-133. doi: 10.1017/S0266462319000059. Epub 2019 Mar 11.
4
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.舒尼替尼或干扰素α治疗转移性肾细胞癌患者的生活质量：一项III期随机试验的结果
J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.
5
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.贝伐单抗联合干扰素α-2a治疗转移性肾细胞癌：一项随机、双盲III期试验。
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
6
Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.
Clin Genitourin Cancer. 2016 Aug;14(4):e347-53. doi: 10.1016/j.clgc.2016.04.021. Epub 2016 May 2.
7
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者中舒尼替尼的预后列线图
Cancer. 2008 Oct 1;113(7):1552-8. doi: 10.1002/cncr.23776.
8
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
9
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.从意大利国家医疗服务体系的角度看，帕唑帕尼与舒尼替尼作为局部晚期或转移性肾细胞癌一线治疗的成本效益
Clin Ther. 2017 Mar;39(3):567-580.e2. doi: 10.1016/j.clinthera.2017.01.017. Epub 2017 Feb 9.
10
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自一项随机、对照、III 期临床试验的疗效和安全性结果的扩展随访。
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16.
引用本文的文献
1
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.CheckMate 214 研究中晚期肾细胞癌患者健康相关生活质量与总生存期的关系
Oncologist. 2024 Jun 3;29(6):511-518. doi: 10.1093/oncolo/oyae003.
2
Health-Related Quality of Life Scores and Values as Predictors of Mortality: A Scoping Review.健康相关生活质量评分和价值观作为死亡率预测因素的研究综述。
J Gen Intern Med. 2023 Nov;38(15):3389-3405. doi: 10.1007/s11606-023-08380-4. Epub 2023 Aug 31.
3
Timely Palliative Care: Personalizing the Process of Referral.及时的姑息治疗：个性化转诊流程
Cancers (Basel). 2022 Feb 18;14(4):1047. doi: 10.3390/cancers14041047.
4
Association of Health-Related Quality of Life with Overall Survival in Older Americans with Kidney Cancer: A Population-Based Cohort Study.美国老年肾癌患者健康相关生活质量与总生存期的关联：一项基于人群的队列研究。
Healthcare (Basel). 2021 Oct 10;9(10):1344. doi: 10.3390/healthcare9101344.
5
Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials.晚期癌症患者健康相关生活质量与无进展生存期的关系：SWOG 临床试验的二次分析。
JCO Oncol Pract. 2022 Apr;18(4):e442-e451. doi: 10.1200/OP.21.00407. Epub 2021 Oct 4.
6
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.在晚期去分化脂肪肉瘤患者中，selinexor 与健康相关的生活质量和疼痛。
Future Oncol. 2021 Aug;17(22):2923-2939. doi: 10.2217/fon-2021-0284. Epub 2021 Apr 15.
7
Targeted therapy for metastatic renal cell carcinoma.转移性肾细胞癌的靶向治疗
Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2.
8
Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).在CABOSUN随机临床试验（联盟）中，一线使用卡博替尼或舒尼替尼治疗晚期肾细胞癌的质量调整生存期。
Cancer. 2020 Dec 15;126(24):5311-5318. doi: 10.1002/cncr.33169. Epub 2020 Oct 6.
9
The role of patient-physician relationship on health-related quality of life and pain in cancer patients.医患关系对癌症患者健康相关生活质量和疼痛的影响。
Support Care Cancer. 2020 Jun;28(6):2615-2626. doi: 10.1007/s00520-019-05070-y. Epub 2019 Oct 16.
10
Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.替沃扎尼对晚期肾细胞癌治疗中患者预后的影响。
Cancer Manag Res. 2019 Aug 16;11:7779-7785. doi: 10.2147/CMAR.S206105. eCollection 2019.
本文引用的文献
1
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.舒尼替尼或干扰素α治疗转移性肾细胞癌患者的生活质量：一项III期随机试验的结果
J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.
2
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.接受血管内皮生长因子靶向治疗的转移性透明细胞肾细胞癌患者预后相关的临床因素。
Cancer. 2007 Aug 1;110(3):543-50. doi: 10.1002/cncr.22827.
3
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.索拉非尼对症状及生活质量的影响：一项肾癌大型随机安慰剂对照研究的结果
Am J Clin Oncol. 2007 Jun;30(3):220-7. doi: 10.1097/01.coc.0000258732.80710.05.
4
Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Tumori. 2007 Jan-Feb;93(1):68-74. doi: 10.1177/030089160709300112.
5
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.
6
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.血小板增多症作为转移性肾细胞癌患者生存的预后因素。
Cancer. 2006 Oct 15;107(8):1793-800. doi: 10.1002/cncr.22237.
7
Can patient satisfaction with quality of life predict survival in advanced colorectal cancer?晚期结直肠癌患者对生活质量的满意度能否预测生存情况？
Support Care Cancer. 2006 Nov;14(11):1104-10. doi: 10.1007/s00520-006-0100-3. Epub 2006 Jul 4.
8
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).癌症治疗功能评估-肾脏症状指数（FKSI）的开发与验证
J Support Oncol. 2006 Apr;4(4):191-9.
9
Prognostic value of thrombocytosis in renal cell carcinoma.血小板增多症在肾细胞癌中的预后价值。
J Urol. 2006 Mar;175(3 Pt 1):859-63. doi: 10.1016/S0022-5347(05)00526-4.
10
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?在晚期结直肠癌患者中，患者自我报告的健康相关生活质量能否在关键生物医学数据之外预测生存情况？
Eur J Cancer. 2006 Jan;42(1):42-9. doi: 10.1016/j.ejca.2005.07.025. Epub 2005 Nov 18.
Zotero 插件